John Libbey Eurotext

Hématologie

MENU

Antimould azole antifungals: indications and therapeutic drug monitoring Volume 22, issue 6, Novembre-Décembre 2016

Figures

  • Figure 1

Tables

Authors
1 Service d’hématologie clinique et de thérapie cellulaire, Groupe hospitalier Albert Chenevier-Henri Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France
2 Université Paris-Est Créteil, Créteil, France
3 Service de Pharmacie, hôpitaux universitaires Paris-Seine-Saint Denis, CHU Avicenne, Bobigny, France
4 Laboratoire de parasitologie-mycologie, Groupe hospitalier Lariboisière-Saint-Louis-Fernand-Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
5 Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
6 Institut Pasteur, CNRS, Molecular Mycology Unit, Centre national de référence mycoses invasives et antifongiques, URA3012, Paris, France
* Tirés à part

Antifungal azoles with antifilamentous activity (itraconazole, voriconazole, posaconazole, isavuconazole) are widely used in the hematology ward for prophylaxis and treatment of invasive fungal infections. However, their gut absorption is very variable, their metabolism is complex and they are associated with drug-drug interactions. Therapeutic drug monitoring is recommended for optimizing the clinical efficacy and reducing drug-related adverse events, both in prophylactic and therapeutic indications.